Redeye initiates coverage on Calmark, a Swedish diagnostics company offering point of care testing for biomarkers in newborns. Commercialization is now starting, and we believe further regulatory approvals are underway. Calmark is rather uniquely positioned, in our view, and our supportive valuation reflects a base case of significant sales ramp-up in 2022-23. While not in our numbers yet, the possibility of Covid-19 relevance adds spice.